Founded in Vienna, United States, CEL-SCI is a biotechnology company focused on developing innovative immunotherapy products for cancer and infectious diseases. The company's core mission is to improve the treatment of cancer, autoimmune, and infectious diseases through advanced research and development. CEL-SCI's flagship product, Multikine, is an immunotherapy treatment designed to enhance the body's natural immune response against tumors. The company targets the oncology market and aims to provide effective therapeutic solutions that can significantly improve patient outcomes.
CEL-SCI has garnered attention through notable affiliations with leading research institutions and investors in the biotech industry. Key achievements include FDA approval for clinical trials of Multikine and significant findings presented at major conferences such as ASCO, ESMO, and ECHNO. The company's pioneering work in immunotherapy has positioned it as a significant player in the biotech sector, contributing to advancements in cancer treatment and offering hope for patients with limited options.
